Immunotherapy for cancer in Delhi has moved from an experimental option to a mainstream part of modern oncology, giving patients a way to fight cancer that works with the body's own defences instead of chemicals alone. Rather than attacking cells directly, it retrains the immune system to recognise and destroy cancer cells it previously missing.
Delhi's hospitals, including Oncare Cancer Hospital, now offer full support for patients seeking immunotherapy for cancer in Delhi, from biomarker testing through to infusion and follow-up care, making the city one of the more accessible places in India to access this treatment.
Immunotherapy is a cancer treatment that helps the immune system find and destroy cancer cells that would otherwise go undetected. It is generally more targeted than conventional chemotherapy and, in select cases, has produced lasting responses even in patients with metastatic disease. Anyone exploring immunotherapy for cancer in Delhi should know it's used alone or combined with surgery, radiation, or chemotherapy depending on the diagnosis.
The drugs used for immunotherapy for cancer in Delhi depend on the cancer type, biomarker results, and treatment goal. Common options include:
Not every patient responds to immunotherapy, which is why biomarker testing comes before treatment, not after.
Results from a general tumor marker panel may also feed into this decision alongside imaging and biopsy findings. This step is what makes immunotherapy for cancer in Delhi a precision-guided decision rather than a one-size-fits-all treatment.
At Oncare, immunotherapy treatments occur in a separate infusion unit specifically designated to administer treatments effectively. Trained infusion nurses keep a close eye on patients' vital signs during treatment and react quickly to any issues. Patients usually finish their treatment in a matter of hours, and are then discharged. The first infusion day includes preparatory treatments and a short observation period before discharge for patients that are uncertain about what the process entails.
Prior to the commencement of immunotherapy, the majority of cases are subjected to a tumour board review wherein medical oncologists, radiologists, and pathologists collectively assess the diagnosis, biomarker findings, and treatment history to arrive at the best suited course of action, opposed to a sole specialist arriving at a decision independently.
Most reactions are manageable when caught early, which is why regular monitoring during treatment matters as much as the treatment itself.
The cost of immunotherapy for cancer in Delhi depends on the drug used, cancer type and stage, number of cycles, and the hospital chosen. Broadly, costs vary by:
Delhi remains among the more affordable cities in India for immunotherapy compared to many other countries offering similar care.
Given that immunotherapy can be expensive, most hospitals including Oncare offer financial counselling alongside treatment. Support options typically include:
A financial counsellor can usually walk patients through these options before treatment starts, so cost isn't a surprise mid-course.
Oncare Cancer Hospital is known for patient-first, evidence-based cancer care. For anyone comparing options for immunotherapy for cancer in Delhi, that means:
The Greater Kailash-1 centre of Oncare, located in South Delhi, provides easy access to immunotherapy for cancer in Delhi for patients from GK, Alaknanda, CR Park, Saket and Lajpat Nagar, stopping patients from having to travel a long distance. As immunotherapy generally involves visiting the facility multiple times for an extended period of time, convenience of its location makes its schedule easier to manage.
Patients who choose immunotherapy for cancer in Delhi get access to advanced drugs, experienced specialists, and coordinated care from diagnosis through recovery. Book a consultation with our specialists to find out if immunotherapy for cancer in Delhi is the right option for your diagnosis.
It can work better in some cancers and usually has fewer side effects, but this depends heavily on the cancer type and biomarker results.
Treatment can run from a few weeks to many months, depending on how the patient responds and tolerates the drug.
Yes, when administered and monitored by a trained oncology team, though immune-related side effects need to be watched for throughout treatment.
It can control or, in some cases, eliminate cancer entirely, particularly when caught early and matched to the right biomarker profile.
Most patients do. Tests like PD-L1 expression, MSI, and tumor mutational burden help doctors confirm whether a patient is likely to respond before starting treatment, rather than relying on trial and error.
From diagnosis to recovery, Oncare's expert oncologists walk with you every step of the way.